Literature DB >> 20433807

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

Filippo Ansaldi1, Marta Zancolli, Paolo Durando, Emanuele Montomoli, Laura Sticchi, Giuseppe Del Giudice, Giancarlo Icardi.   

Abstract

MF59 is already known to enhance the breadth of antibody response to mismatched influenza seasonal and avian strains. However, little is known on the effect of MF59 on immunogenicity of influenza vaccines when "apparent" good matching between circulating and vaccine strains exists. To this end, we compared the immune response elicited by MF59-adjuvanted or non-adjuvanted subunit vaccine, containing A/California/7/04(H3N2) strain, against circulating viruses isolated between 2004/2005 and 2006/2007 seasons, belonging to different clades. The advantage offered by MF59 in terms of higher immunogenicity, expressed as higher post-vaccination HI titres, is observable also against viruses showing antigenic and molecular pattern undistinguishable from vaccine strain, but it became even more evident as the antigenic and molecular distance between vaccine and circulating strains grew. These data show that seasonal influenza vaccine adjuvanted with MF59 can offer a stronger benefit as compared to non-adjuvanted vaccine in protecting against a broader range of virus strains circulating during the influenza season. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433807     DOI: 10.1016/j.vaccine.2010.04.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

2.  Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Authors:  Davide Bedognetti; Gabriele Zoppoli; Carlotta Massucco; Elisa Zanardi; Simonetta Zupo; Andrea Bruzzone; Mario Roberto Sertoli; Enrico Balleari; Omar Racchi; Marco Messina; Graziano Caltabiano; Giancarlo Icardi; Paolo Durando; Francesco M Marincola; Francesco Boccardo; Manlio Ferrarini; Filippo Ansaldi; Andrea De Maria
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

3.  Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.

Authors:  Satoshi Hiroi; Saeko Morikawa; Keiko Nakata; Akiko Maeda; Tsuneji Kanno; Shin Irie; Satoko Ohfuji; Yoshio Hirota; Tetsuo Kase
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Authors:  Barbara Camilloni; Michela Basileo; Stefano Valente; Emilia Nunzi; Anna Maria Iorio
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis.

Authors:  Tiffany W Y Ng; Benjamin J Cowling; Hui Zhi Gao; Mark G Thompson
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

Review 6.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

7.  Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.

Authors:  Joon Young Song; Hee Jin Cheong; Yu Bin Seo; In Seon Kim; Ji Yun Noh; Jung Yeon Heo; Won Suk Choi; Jacob Lee; Woo Joo Kim
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

8.  Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets.

Authors:  Judith M A van den Brand; Joost H C M Kreijtz; Rogier Bodewes; Koert J Stittelaar; Geert van Amerongen; Thijs Kuiken; James Simon; Ron A M Fouchier; Giuseppe Del Giudice; Rino Rappuoli; Guus F Rimmelzwaan; Albert D M E Osterhaus
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

9.  Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-21

Review 10.  Aging of the immune system: Focus on inflammation and vaccination.

Authors:  Marcello Pinti; Victor Appay; Judith Campisi; Daniela Frasca; Tamas Fülöp; Delphine Sauce; Anis Larbi; Birgit Weinberger; Andrea Cossarizza
Journal:  Eur J Immunol       Date:  2016-10       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.